

BIOSYNTHESIS OF IRIDOID GLUCOSIDES IN *GALIUM MOLLUGO*, *G. SPURIUM* VAR. *ECHINOSPERMON* AND *DEUTZIA CRENATA*. INTERMEDIACY OF DEOXYLOGANIC ACID, LOGANIN AND IRIDODIAL GLUCOSIDE*

SHINICHI UESATO, MASAO MIYAUCHI, HIROYUKI ITOH and HIROYUKI INOUE

Faculty of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606, Japan

(Received 19 November 1985)

Key Word Index—*Galium mollugo*; *G. spurium* var. *echinospermon*; Rubiaceae; *Deutzia crenata*; Saxifragaceae; Philadelphaceae; iridoid glucoside; biosynthesis; ^2H NMR.

Abstract—Administration of ^2H -labelled compounds to *Galium mollugo*, *G. spurium* var. *echinospermon* and *Deutzia crenata* established that deoxyloganic acid is a precursor of asperuloside, geniposidic acid and secogalioside in *G. mollugo* as well as asperuloside in *G. spurium*, while iridodial glucoside is a precursor of deutzioside in *D. crenata*. Additionally, the intermediacy of loganic acid in the biosynthesis of the iridoid and secoiridoid glucosides in the *Galium* plants was reconfirmed.

INTRODUCTION

By administration of various ^3H -labelled compounds to *Daphniphyllum macropodum*, *Aucuba japonica* etc., we provided evidence that iridoid glucosides including geniposide (1), asperuloside (2) and aucubin (3), all of which have a highly oxidized cyclopentane ring, are biosynthesized via deoxyloganic acid (4), loganic acid (5) and 10-deoxygeniposidic acid (6) [1, 2]. Subsequently, we found that iridodial (7) functions as a key intermediate for the biosynthesis of lamiide (8) and lamioside (9) in *Lamium amplexicaule*, deutzioside (10) in *Deutzia crenata* and asperuloside (2) in *Galium spurium* var. *echinospermon* [3] as well as patrinose (11) in *Patrinia gibbosa* [4]. Very recently, we demonstrated the precursorship of iridodial (7) for the biosynthesis of secologanin (12) (in *Lonicera morrowii* [5, 6]), vindoline (13) (in *Catharanthus roseus* [5–7]) and ajmaline (14) and vomilenine (15) (in *Rauwolfia serpentina* cell cultures [7, 8]); these compounds had already been shown to be formed via deoxyloganin (16) and loganin (17). In contrast to these findings, Damtoft reported recently that 8-epideoxyloganin (18) with 8*R*-configuration is a precursor of lamiide (8) and ipolamiide (19) in *Hebenstreitia dentata* and 8-epideoxyloganic acid (20) is a precursor of aucubin (3) in *Scrophularia racemosa* and *Plantago major* and antirrhinoside (21) in *Antirrhinum majus*, while the 8*S*-isomers, deoxyloganin (16) and deoxyloganic acid (4), are not precursors of these glucosides [9, 10]. The involvement of 8*R*-isomers, 8-epiiridodial (22) and 8-epiiridodial glucoside (boschnalioside) (23), was also demonstrated by us for the biosynthesis of tarennoside (24) and gardenoside (25) in *Gardenia jasminoides* cell cultures [11, 12].

Thus, the biosynthetic pathways of 8, 19, 3, 21, 24 and 25, which were originally considered to be biosynthesized by the same route, seem to differ depending on the kind of plant. However, account must be taken of the fact that the ^3H -labelled deoxyloganic acid (4), deoxyloganin (16) and iridodial (7) used for our feeding experiments were each recently found to contain ca 10% of the 8*R*-isomer. Thus the high resolution ^1H NMR spectrum of deoxyloganin tetraacetate (27) obtained by Pd/C-catalyzed hydrogenation of geniposide pentaacetate (26) showed a doublet ($J = 6.8$ Hz) at δ 1.03 due to the C-10 methyl protons and a doublet ($J = 1.0$ Hz) at δ 7.30 due to the C-3 vinyl proton as well as signals at δ 1.01 (d , $J = 6.8$ Hz) and 7.35 (d , $J = 1.0$ Hz) due to the corresponding protons of 8-epideoxyloganin tetraacetate (28). Judging from these signal intensities, the ratio of the two compounds was about 9 to 1. The same ratio of 8*S*- to 8*R*-isomer was also obtained in the hydrogenation of asperuloside tetraacetate (29) to deoxyloganic acid tetraacetate (30). In the present work, we therefore examined whether asperuloside (2), deutzioside (10) and the related glucosides are biosynthesized through 8*S*-compounds such as 4, 7 and 16 or through the corresponding 8*R*-isomers.

RESULTS AND DISCUSSION

In order to examine the above problem the following ^2H -labelled putative precursors were synthesized and administered to *G. mollugo*, *G. spurium* var. *echinospermon* and *D. crenata*: deoxyloganic acid (4), 8-epideoxyloganic acid (20), iridodial glucoside (31), iridodial glucoside (32) and 8-epiiridodial glucoside (33). Among the above plants, *G. mollugo* is unusual in that it contains not only the highly oxidized iridoid glucosides 10-hydroxyloganin (34), asperuloside (2) and geniposidic acid (35), but also the secoiridoid glucosides secogalioside (36) and 10-hydroxymorroniside (37) [13, 14]. Therefore, $[7\text{-}^2\text{H}]\text{loganic acid}$ (5) and, as a reference, $[7\text{-}^2\text{H}]\text{-7-epiloganic acid}$ (38) were also synthesized and adminis-

* Part 58 in the series "Studies on monoterpene glucosides and related natural products". For Part 57 see ref. [12].

tered to this plant in order to examine the pathway after deoxyloganic acid (4).

^2H -Labelled precursors required for the feeding experiments were prepared in the following way.

[7,8,10- $^2\text{H}_5$]- and [10- $^2\text{H}_3$]-8-Epideoxyloganic acid (20). [10- $^2\text{H}_2$] Geniposide pentaacetate (26) [15] was reduced with NaB^2H_4 in the presence of $\text{Pd}(\text{PPh}_3)_4$ and PPh_3 to give a mixture of [10- $^2\text{H}_3$]-10-deoxygeniposide tetraacetate (39) and [7,10- $^2\text{H}_3$]-7-deoxygardoside methyl ester tetraacetate (40) in a ratio of 4 to 1 [12]. This mixture was hydrogenated with deuterium over 5% Rh-C [9] to give [7,8,10- $^2\text{H}_5$]-8-epideoxyloganin tetraacetate (28). In the ^1H NMR spectrum of 28, the signals due to the C-3 vinyl proton were observed at δ 7.35 and δ 7.30 in an intensity ratio of 97 to 3. Moreover, the signal intensity due to the C-10 methyl proton at δ 1.01 was reduced by 88% relative to that of the unlabelled counterpart. Thus, this compound contained 3% of the 8S-isomer, deoxyloganin tetraacetate (27), and about 2.6 protons of its C-10 methyl group were replaced by deuterium. Alkaline hydrolysis gave [7,8,10- $^2\text{H}_5$]-8-epideoxyloganic acid (20).

[10- $^2\text{H}_3$]-10-Deoxygeniposide tetraacetate (39) [15] was hydrogenated over 5% Rh-C to yield [10- $^2\text{H}_3$]-28. Its ^1H NMR spectrum indicated contamination with 10% [10- $^2\text{H}_3$]-27 as well as the replacement of 71% (corresponding to 2.1 protons) of the C-10 methyl protons with deuterium. Alkaline hydrolysis yielded [10- $^2\text{H}_3$]-8-epi-deoxyloganic acid (20).

[7,8,10- $^2\text{H}_5$]Deoxyloganic acid (4). [10- $^2\text{H}_2$]Geniposide pentaacetate (26) [15] was hydrogenated with deuterium over 5% Pd-C leading to [7,8,10- $^2\text{H}_5$]deoxyloganin tetraacetate (27). Its ^1H NMR spectrum indicated contamination with 7% of the 8R-isomer as well as replacement of 76% (corresponding to 2.3 protons) of the C-10 methyl protons by deuterium. Alkaline hydrolysis yielded [7,8,10- $^2\text{H}_5$]deoxyloganic acid (4).

[7,8,10- $^2\text{H}_5$]Iridotrial glucoside (31). [7,8,10- $^2\text{H}_5$]Deoxyloganin tetraacetate (27) was reduced with $\text{LiAlH}_2(\text{OMe})_2$ followed by Pt-catalyzed oxidation to furnish [7,8,10- $^2\text{H}_5$]iridotrial glucoside (31).

[11- ^2H]Iridodial glucoside (32). 11-Hydroxyiridodial glucoside pentaacetate (41) derived by $\text{LiAlH}_2(\text{OMe})_2$ reduction of deoxyloganin tetraacetate (27) (containing 7% of the corresponding 8R-isomer) was subjected to hydrogenolysis with deuterium over 5% Pd-C leading to [11- ^2H]iridodial glucoside tetraacetate (42), which on Zemplen reaction yielded [11- ^2H]iridodial glucoside (32). Its ^1H NMR spectrum showed a 28% reduction of the signal intensity of the C-11 methyl protons indicating the introduction of about 0.84 deuterium into the C-11 position.

[11- ^2H]-8-Epiiridodial glucoside (33). 8-Epi-11-hydroxyiridodial glucoside pentaacetate (43) derived from 8-epideoxyloganin tetraacetate (28) (containing 2% of the corresponding 8S-isomer) was subjected to hydrogenolysis with deuterium over 5% Pd-C to give [11- ^2H]-8-epiiridodial glucoside tetraacetate (44) [12], which was deacetylated to [11- ^2H]-8-epiiridodial glucoside (33). Its ^1H NMR spectrum indicated the replacement of about 0.87 proton at the C-11 position by deuterium.

[7- ^2H]Loganic acid (5) and [7- ^2H]-7-epiloganic acid (38). Reduction of 7-dehydrologanin tetraacetate (45) [16] with NaB^2H_4 gave [7- ^2H]-7-epiloganin tetraacetate (46). Subsequent inversion [16, 17] of the 7-hydroxy group gave [7- ^2H]loganin pentaacetate (47). The ^1H NMR spectra of both 46 and 47 lacked the signals due

to the C-7 protons (around δ 3.80 and δ 5.15, respectively). Zemplen reaction and alkaline hydrolysis of the 47 yielded [7- ^2H]loganic acid (5), whereas alkaline hydrolysis of 46 gave [7- ^2H]-7-epiloganic acid (38).


Feeding experiments

Initially, [7,8,10- $^2\text{H}_5$]deoxyloganic acid (4), [7,8,10- $^2\text{H}_5$]-8-epideoxyloganic acid (20) and [7,8,10- $^2\text{H}_5$]iridotrial glucoside (31) were administered separately to *G. mollugo* plants. After 6 days, asperuloside (2), seco-galioside (36) and geniposidic acid (35) were isolated. The latter was further purified after methylation to geniposide (1). In the ^2H NMR spectra (measured in MeCN), only the glucosides isolated from the plants fed with [7,8,10- $^2\text{H}_5$]deoxyloganic acid (4) showed signals, i.e. in asperuloside (2) the ^2H -peaks appeared at δ 5.79 and δ 4.65 due to the C-7 vinyl and C-10 methylene deuterium, in geniposide (1) at δ 5.82 and δ 4.24 due to the C-7 vinyl and C-10 methylene deuterium, and in secogalioside (36) at around δ 5.60 due to the C-10 deuterium. The incorporation ratios of ^2H -labelled 4 into the above glucosides were calculated using the respective percentage ^2H enrichments of these C-10- ^2H signals, which were normalized relative to the ^2H -signal due to the natural abundance of deuterium in the MeCN (δ 1.95) used as the solvent. The incorporation ratios (Table 1) of [7,8,10- $^2\text{H}_5$]-4 into 2, 35 and 36 were fairly high. In addition, the higher specific incorporation of 4 into 35 than into 2 supported the precursorship of 35 for the biosynthesis of 2.


Subsequently, [7,8,10- $^2\text{H}_5$]deoxyloganic acid (4) and [10- $^2\text{H}_3$]-8-epideoxyloganic acid (20) were fed separately to the congeneric plant, *G. spurium* var. *echinospermon* which contains only asperuloside (2) as the iridoid. The incorporation ratios (Table 2) of these compounds into 2 calculated in the same way from the ^2H NMR spectra indicated that 4 was also the precursor of 2 in *G. spurium*. Although 20 was incorporated into 2 to a significant extent, the possibility of 20 serving as a biosynthetic precursor of 2 seems doubtful, since the differences between the total and specific incorporations of 4 and 20 into 2 would become much higher than the values obtained, in consideration of the fact that 4 was contaminated with 7% of 20, while 20 was contaminated with 10% of 4.

From the results mentioned so far, it was concluded that the iridoid and secoiridoid glucosides in the *Galium* plants were biosynthesized via deoxyloganic acid (4) with 8S-configuration in accordance with our previous proposal [2]. This conclusion coincides with the recent report of Damtoft *et al.* [18] that administration of deoxyloganic acid (4) and 8-epideoxyloganic acid (20) to *Theligonum cynocrambe* (Rubiaceae) gave a 2% incorporation of 4 into asperuloside (2) while 20 was not incorporated. The non-incorporation of iridotrial glucoside (31) into 2, 35 and 36 in *G. mollugo* suggests that glucosidation may be at the level of the aglucone of deoxyloganic acid (4).


Asperuloside (2) was previously demonstrated by us to be biosynthesized via loganic acid (5), 10-deoxygeniposidic acid (6) and geniposidic acid (35) [2]. Furthermore, secogalioside (36), belonging to the secoiridoid glucosides, is naturally presumed to be formed via loganic acid (5) or loganin (17). In order to prove this presumption, administration of [7- ^2H]loganic acid (5) and [7- ^2H]-7-epiloganic acid (38) to *G. mollugo* was carried out. The incorporation of the above glucosides into 2, 35 and 36 were calculated




1 R = H
26 R = Ac




3




8 R = OH
19 R = H




9




11




13




14




15




16 R = H, R' = Me
27 R = Ac, R' = Me
30 R = Ac, R' = H




18 R = H, R' = Me
20 R = R' = H
28 R = Ac, R' = Me




21




22




23 (8R)
31 (8S)




24




25




29




33 (8R) R = H
42 (8S) R = Ac
44 (8R) R = Ac




34




37




38 (7R) R = R' = H
46 (7R) R = Ac, R' = Me
47 (7S) R = Ac, R' = Me




39 7, 8 - dehydro
40 8, 10 - dehydro



41 (8S)
43 (8R)



45



48

Table 1. Administration of ^2H -labelled putative precursors to *G. mollugo*

Compounds fed	Amount (mg)	Amount of plant material (g)	Metabolic period (days)	Amount (mg) of glucosides isolated and (second line) total incorporation and sp. incorporation (%)		
				2	35	36
[7,8,10- $^2\text{H}_5$]-4	9.2	17.7	6	43.2 30.3 (6.9)	9.2 19.6 (19.7)	26.5 9.4 (3.5)
[7,8,10- $^2\text{H}_5$]-20	11.7	16.2	6	33.8 0 (0)	10.3 0 (0)	24.6 0 (0)
[7,8,10- $^2\text{H}_5$]-31	11.9	17.1	6	30.4 0 (0)	6.7 0 (0)	31.5 0 (0)
[7- ^2H]-5	12.9	18.3	4	54.8 37.9 (9.8)	6.8 29.3 (57.3)	13.5 10.0 (10.7)
[7- ^2H]-38	11.5	15.9	4	44.7 0 (0)	— —	12.4 0 (0)

Table 2. Administration of ^2H -labelled deoxyloganic acid (4) and 8-epideoxyloganic acid (20) to *G. spurium* var. *echinospermon*

Compounds fed and amount (mg)	Amount of plant material (g)	Metabolic period (days)	Asperuloside (2) isolated		
			Amount (mg)	Total incorporation (%)	Sp. incorporation (%)
[7,8,10- $^2\text{H}_5$]-4 16.3	23.6	4	65.0	14.9	3.4
[10- $^2\text{H}_5$]-20 14.1	22.3	4	75.0	2.7	0.6

in the usual manner from the ^2H NMR spectra. As shown in Table 1, loganic acid (5) was incorporated into all these glucosides in high ratios, while 7-epiloganic acid (38) was not incorporated into any glucoside. The marked difference between the specific incorporation ratios of 5 into 35 and 2 corroborated the above-mentioned route, i.e. loganic acid (5) \rightarrow 10-deoxygeniposidic acid (6) \rightarrow geniposidic acid (35) \rightarrow asperuloside (2).

Finally, [11- ^2H]iridodial glucoside (32) and [11- ^2H]-8-epiiridodial glucoside (33) were administered separately to *D. crenata*. The ^2H NMR spectra (CHCl_3) of the pentaacetate (48) of isolated deutzioside (10) showed signals at δ 1.48 (11- ^2H) originating from the ^2H -labelled 32 and 33. Total and specific incorporation ratios (Table 3) were calculated by comparing the intensities of these signals with that of the natural abundance of deuterium in CHCl_3 (at δ 7.25) used as the solvent.

It was found that the incorporation of iridodial glucoside (32) with 8*S*-configuration into 10 was much higher than that of 8-epiiridodial glucoside (33) with 8*R*-configuration. Considering the fact that 32 was contaminated with 7% 33, while 33 was contaminated with 2% 32, the differences between the specific and total incorporation ratios of 32 and 33 would become much larger. Therefore, it was also confirmed that deutzioside (10) was biosynthesized via iridodial (7) and iridodial glucoside (32) in accord with our previous result [3].

The present work corroborated our proposals that the iridoid and secoiridoid glucosides in *Galium* are biosynthesized via deoxyloganic acid (4), while the iridoid glucosides in *Deutzia* are formed via iridodial glucoside


(32). This result is in contrast to those obtained in the feeding experiments with *Gardenia jasminoides* suspension cultures where tarennoside (24) [and hence, the subsequently formed geniposidic acid (35)] is biosynthesized via (8*R*)-precursors such as boschnalioside (23) [11, 12]. In *Galium*, 35 is formed via (8*S*)-compounds such as deoxyloganic acid (4). This is an example of the biosynthesis of identical iridoid glucosides by different pathways depending on the kind of plant.

It remains to be clarified whether aucubin (3) in *Aucuba* and lamiide (8) and lamioside (9) in *Lamium* are formed via deoxyloganic acid (4) or via 8-epideoxyloganic acid (20); this problem is intriguing since 20 was shown by Damtoft to be a precursor of the above iridoid glucosides in plants of other genera [9, 10].

EXPERIMENTAL

Mps: uncorr.; ^1H NMR: 199.50 MHz, CDCl_3 (acetates) or CD_3OD (free glucosides), TMS as internal standard; ^2H NMR: 30.63 MHz, MeCN (free glucosides) or CHCl_3 (acetates), natural abundant deuterium as internal standard. CC: silica gel 60 (70–230 mesh) (Merck) and activated charcoal (Wako); TLC and prep. TLC: silica gel 60 GF₂₅₄ (Merck) (0.3 mm) and PF₂₅₄ (Merck) (1.0 mm). Spots and bands were visualized by UV (254 nm) or by exposure to I_2 vapour. The main bands on prep. TLC plates were scraped off and extracted with CHCl_3 -MeOH (9:1) and extracts were concd *in vacuo*.

Plant materials for feeding experiments. *G. mollugo* plants cultivated at the Medical Plant Garden, Faculty of Pharmaceutical Sciences, Kyoto University [14] were collected in



Scheme 1. Biosynthetic pathway of asperuloside (2), geniposidic acid (35), secogalioside (36) and deutzioside (10).

May, 1983; *G. spurium* var. *echinospermon* plants were collected on the campus of this faculty in May, 1983; *D. crenata* twigs were collected on the campus of the Faculty of Medicine, in Oct., 1983.

Conversion of [10- 2 H $_2$]geniposide pentaacetate (26) into [7,8,10- 2 H $_3$]-8-epideoxyloganin tetraacetate (28). 2 H-Labelled 26 [15] (584 mg) was reduced with NaB 2 H $_4$ (97% 2 H) (102 mg) in the presence of Pd(PPh $_3$) $_4$ (111 mg) and PPh $_3$ (182 mg) according to the procedure described in the preceding paper [12] to yield a 4:1 mixture (367 mg) of [10- 2 H $_3$]-10-deoxygeniposide tetraacetate (39) and [7,10- 2 H $_3$]-7-deoxygardoside methyl ester tetraacetate (40) as colourless needles, mp 105–106°. A soln of this mixture in MeOH (5 ml) was hydrogenated with 2 H $_2$ gas over 5% Rh-C until the uptake of 2 H $_2$ had ceased. The usual work-up gave a solid (384 mg), which was purified by prep. TLC (Et $_2$ O) and recrystallization from EtOH to yield [7,8,10- 2 H $_3$]-8-epideoxyloganin tetraacetate (28) (214 mg) as colourless needles,

mp 108–109°. 1 H NMR: δ 1.01 (*d*, *J* = 6.8 Hz, 10-H $_3$ \times 0.12), 1.94–2.09 (OAc \times 4), 2.83–2.89 (*m*, 5-H), 3.70 (COOCH $_3$), 7.30 [*d*, *J* = 1.0 Hz, 3-H \times 0.03 (27)], 7.35 (*d*, *J* = 1.0 Hz, 3-H \times 0.97).

Alkaline hydrolysis of [7,8,10- 2 H $_3$]-28. A suspension of [7,8,10- 2 H $_3$]-28 (42 mg) in 0.5 M NaOH (20 ml) was stirred vigorously at room temp. for 1.5 hr. The resultant soln was neutralized with Amberlite IR-120 (H $^+$ -form) and concd *in vacuo*. The residue (25 mg) was subjected to prep. TLC (CHCl $_3$ -MeOH 7:3, two developments) to yield [7,8,10- 2 H $_3$]-8-epideoxyloganic acid (20) as a white powder (12.0 mg): 1 H NMR: δ 1.06 (*m*, 10-H $_3$ \times 0.12), 2.85–2.96 (*m*, 9-H), 3.59–3.94 (*m*, 6'-H $_2$), 4.67 [*d*, *J* = 7.8 Hz, 1'-H \times 0.03 (4)], 4.69 (*d*, *J* = 7.6 Hz, 1'-H \times 0.97), 5.20 [*d*, *J* = 5.9 Hz, 1-H \times 0.03 (4)], 5.45 (*d*, *J* = 5.4 Hz, 1-H \times 0.97), 7.42 (*d*, *J* = 1.2 Hz, 3-H).

Conversion of [10- 2 H $_3$]-10-deoxygeniposide tetraacetate (39) into [10- 2 H $_3$]-8-epideoxyloganic acid (20). A soln of [10- 2 H $_3$]-39

Table 3. Administration of 2 H-labelled iridodial glucoside (32) and 8-epiiridodial glucoside (33) to *D. crenata*

Compounds fed and amount (mg)	Amount of plant material (g)	Metabolic period (days)	Deutzioside pentaacetate (48)		
			Amount (mg)	Total incorporation (%)	Sp. incorporation (%)
[11- 2 H]-32 7.0	4.9	1	18.2	17.9	10.4
[11- 2 H]-33 6.7	4.7	1	18.8	4.3	2.4

[15] (305 mg) in MeOH (4 ml) was hydrogenated with H_2 gas over 5% Rh-C (80 mg) in the same way as for the preparation of [7,8,10- 2H_3]-28 to yield a colourless solid (271 mg). Recrystallization from EtOH gave [10- 2H_3]-8-epideoxyloganin tetraacetate (28) (202 mg) as colourless needles, mp 107–108°. Its 1H NMR spectrum indicated contamination with 10% [10- 2H_3]-27 as well as replacement of 71% of the C-10 methyl protons [δ 1.01 (*s, br*)] by 2H . An aliquot (45 mg) of this compound was suspended in 0.5 M NaOH (30 ml) and the mixture was stirred at room temp. for 4 hr. The resultant soln was neutralized with Amberlite IR-120 (H^+ -form) and concd *in vacuo* to give a powdery residue (30 mg), which on prep. TLC ($CHCl_3$ -MeOH 7:3, two developments) gave [10- 2H_3]-8-epideoxyloganic acid (20) (24.5 mg) as a white powder. Its 1H NMR spectrum indicated contamination with 10% [10- 2H_3]-4 as well as replacement of 71% of the C-10 methyl protons [δ 1.06 (*s, br*)] by 2H .

[7,8,10- 2H_3]Deoxyloganic acid (4). A soln of [10- 2H_3]-geniposide pentaacetate (26) (162 mg) in MeOH (4 ml) was hydrogenated with 2H_2 gas over 5% Pd-C (131 mg) until the uptake of H_2 had ceased. The mixture was filtered and concd *in vacuo* to give a residue (164 mg), whose prep. TLC (Et_2O -*n*-hexane- C_6H_6 , 6:1:1) gave a colourless solid (119 mg). Recrystallization from EtOH furnished [7,8,10- 2H_3]deoxyloganin tetraacetate (27) as colourless needles (62 mg), mp 115°. 1H NMR: δ 1.03 [*s (br)*, 10- $H_3 \times 0.24$], 1.93–2.12 (OAc $\times 4$), 3.67 (COOCH $_3$), 4.13–4.32 (*m*, 6'- H_2), 4.84 (*d*, $J = 8.1$ Hz, 1'- H), 7.30 (*d*, $J = 1.0$ Hz, 3-H $\times 0.93$), 7.35 [*d*, $J = 1.0$ Hz, 3-H $\times 0.07$ (28)]. An aliquot (24 mg) of this compound was hydrolyzed by stirring in 0.5 M NaOH (30 ml). The usual work-up gave [7,8,10- 2H_3]deoxyloganic acid (4) (containing 7% [7,8,10- 2H_3]-20) (9.2 mg) as a white powder. 1H NMR: δ 1.04 [*s (br)*, 10- $H_3 \times 0.29$], 2.81–2.92 (*m*, 9-H), 3.65–3.92 (*m*, 6'- H_2), 4.67 (*d*, $J = 7.8$ Hz, 1'- $H \times 0.93$), 4.69 [*d*, $J = 7.6$ Hz, 1'- $H \times 0.07$ (20)], 5.20 (*d*, $J = 5.9$ Hz, 1-H $\times 0.93$), 5.45 [*d*, $J = 5.4$ Hz, 1-H $\times 0.07$ (20)], 7.36 (*d*, $J = 1.0$ Hz, 3-H $\times 0.93$), 7.41 [*d*, $J = 1.2$ Hz, 3-H $\times 0.07$ (20)].

[7,8,10- 2H_3]Iridodial glucoside (31). [7,8,10- 2H_3]Deoxyloganin tetraacetate (27) (151 mg) (5 ml) was reduced in dry THF (20 ml) with $LiAlH_2(OMe)_2$ [prepared from $LiAlH_4$ (420 mg) and dry MeOH (0.85 ml)] according to the method reported earlier [15]. A soln of the resultant reduction product (62 mg) in H_2O (1.5 ml) was added to a stirred suspension of Pt [prepared from PtO_2 (39 mg)] in H_2O (3.0 ml); the stirring was continued under an O_2 atmosphere at room temp. for 28 hr. After removal of the catalyst, the soln was concd *in vacuo* to give a residue (63 mg), which on prep. TLC ($CHCl_3$ -MeOH, 4:1, two developments) gave [7,8,10- 2H_3]iridodial glucoside (31) (41 mg) as a white powder. 1H NMR: δ 1.07 [*s (br)*, 10- $H_3 \times 0.29$], 3.62–3.93 (*m*, 6'- H_2), 4.69 (*d*, $J = 7.8$ Hz, 1'- H), 5.41 (*d*, $J = 4.6$ Hz, 1-H $\times 0.93$), 5.62 [*d*, $J = 3.9$ Hz, 1-H $\times 0.07$ (23)], 7.35 (*d*, $J = 0.7$ Hz, 3-H), 9.20 (*s*, 11-CHO).

[11- 2H]Iridodial glucoside (32). A soln of 11-hydroxyiridodial glucoside pentaacetate (41) [15] (138 mg) in MeOH (5 ml) was subjected to hydrogenolysis with 2H_2 gas over 5% Pd-C (96 mg). The mixture was filtered and the soln concd *in vacuo* to give a residue (120 mg), which on prep. TLC (Et_2O) gave a solid (92 mg). On recrystallization from EtOH, [11- 2H]iridodial glucoside tetraacetate (42) (57 mg) was obtained as colourless needles, mp 141–143°. 1H NMR: δ 1.03 (*d*, $J = 5.6$ Hz, 10- H_3), 1.47 [*s (br)*, 11- $H_3 \times 0.72$], 1.98–2.09 (OAc $\times 4$), 3.68–3.76 (*m*, 5-H), 4.07–4.36 (*m*, 6'- H_2), 4.87 (*d*, $J = 8.1$ Hz, 1'- H), 5.86 [*s (br)*, 3-H $\times 0.93$], 5.92 [*s (br)*, 3-H $\times 0.07$ (44)]. 0.1 M methanolic NaOMe (0.2 ml) was added to a soln of [11- 2H]-42 (57 mg) in dry MeOH (3 ml) and the mixture was refluxed for 5 min. After cooling, the mixture was neutralized with Amberlite IR-120 (H^+ -form) and concd *in vacuo*. The residue (32 mg) was subjected to prep. TLC ($CHCl_3$ -MeOH, 4:1 two developments) to yield [11-

2H]iridodial glucoside (32) (29.6 mg) as a white powder. 1H NMR: δ 1.06 (*d*, $J = 6.3$ Hz, 10- H_3), 1.52 [*s (br)*, 11- $H_3 \times 0.72$], 3.62–3.91 (*m*, 6'- H_2), 4.64 (*d*, $J = 7.8$ Hz, 1'- H), 5.05 (*d*, $J = 4.9$ Hz, 1-H $\times 0.93$), 5.28 [*d*, $J = 2.9$ Hz, 1-H $\times 0.07$ (33)], 5.92 [*s (br)*, 3-H $\times 0.07$ (33)], 5.97 (*d*, $J = 1.2$ Hz, 3-H $\times 0.93$).

[11- 2H]-8-Epiiridodial glucoside (33). A soln of 8-epi-11-hydroxyiridodial glucoside pentaacetate (43) [12] (141 mg) in MeOH (5 ml) was subjected to hydrogenolysis with 2H_2 gas over 5% Pd-C (102 mg). After removal of the catalyst, the soln was concd *in vacuo* to give a residue (108 mg). Purification by prep. TLC (Et_2O) and recrystallization from EtOH furnished [11- 2H]-8-epiiridodial glucoside tetraacetate (44) as colourless needles (68 mg), mp 120°. This compound was deacetylated in a similar manner to that described above and the product (34 mg) was subjected to prep. TLC ($CHCl_3$ -MeOH, 4:1, two developments) to yield [11- 2H]-8-epiiridodial glucoside (33) (28.7 mg) as a white powder. It was shown to contain 2% iridodial glucoside (32) by 1H NMR. 1H NMR: δ 1.05 (*d*, $J = 7.1$ Hz, 10- H_3), 1.15–1.83 (*m*, 6- H_2 and 7- H_2), 1.52 [*s (br)*, 11- $H_3 \times 0.71$], 2.09–2.36 (*m*, 8-H and 9-H), 2.45–2.64 (*m*, 5-H), 3.60–3.91 (*m*, 6'- H_2), 4.62 (*d*, $J = 7.8$ Hz, 1'- H), 5.05 [*d*, $J = 4.9$ Hz, 1-H $\times 0.02$ (32)], 5.28 (*d*, $J = 2.9$ Hz, 1-H $\times 0.98$), 5.96 [*s (br)*, 3-H].

[7- 2H]Loganic acid (5). NaB^2H_4 (145 mg) was added to a stirred soln of 7-dehydrologanin tetraacetate (45) (1580 mg) in MeOH (30 ml) under ice cooling, and the stirring was continued for 10 min under the same conditions. The mixture was diluted with H_2O (300 ml) and extracted with $CHCl_3$ (100 ml $\times 3$). The $CHCl_3$ layer was washed with H_2O (200 ml $\times 2$), dried and concd *in vacuo* to give a solid. Recrystallization from Et_2O gave [7- 2H]-7-epi-loganin tetraacetate (46) (1140 mg) as colourless needles, mp 150–151°. 1H NMR: δ 1.11 (*d*, $J = 6.4$ Hz, 10- H_3), 1.94–2.10 (OAc $\times 4$), 3.70 (COOCH $_3$), 4.13–4.35 (*m*, 6'- H_2), 4.86 (*d*, $J = 8.1$ Hz, 1'- H), 7.32 (*d*, $J = 1.2$ Hz, 3-H). The 7-H signal around at δ 3.80 was not observed.

The above compound [7- 2H]-46 was tosylated with C_6H_5N (2 ml) and *p*-toluenesulfonyl chloride (295 mg) and the product was recrystallized from EtOH to give [7- 2H]-7-epi-7-tosylloganin tetraacetate (793 mg) as colourless needles, mp 113–115°. This compound (489 mg) was added to a soln of tetraethylammonium acetate (765 mg) in dry Me_2CO (10 ml) and the whole was refluxed at 56–60° for 24 hr under N_2 and then the solvent was removed *in vacuo*. The residue was taken up in $CHCl_3$ (50 ml) and the $CHCl_3$ soln was washed with H_2O (100 ml $\times 2$), dried and concd *in vacuo*. The resulting brownish residue (866 mg) was chromatographed on silica gel (35 g) with $CHCl_3$ as an eluent to give [7- 2H]loganin pentaacetate (47) (176 mg) as colourless needles, mp 140–141°, the 1H NMR spectrum of which did not show the 7-proton signal at around δ 5.15. Subsequently, [7- 2H]-47 (73 mg) was deacetylated with NaOMe in the usual way to give a solid. Purification by prep. TLC ($CHCl_3$ -MeOH, 4:1, two developments) and recrystallization from EtOH- Me_2CO gave [7- 2H]loganin (17) (35 mg) as colourless needles, mp 218–220°.

This substance was dissolved in 0.5 M NaOH (23 ml) and the whole was stirred at room temp for 15 min. After neutralization with Amberlite IR-120 (H^+ -form), the mixture was concd *in vacuo* to give a white powder (33 mg), which on prep. TLC ($CHCl_3$ -MeOH, 7:3, two developments) furnished [7- 2H]-loganic acid (5) (22 mg) as a white powder. 1H NMR: δ 1.09 (*d*, $J = 6.8$ Hz, 10- H_3), 3.61–3.93 (*m*, 6'- H_2), 4.65 (*d*, $J = 7.5$ Hz, 1'- H), 5.27 (*d*, $J = 4.4$ Hz, 1-H), 7.36 (*d*, $J = 1.0$ Hz, 3-H).

[7- 2H]-7-Epiloganic acid (38). [7- 2H]-7-epiloganin tetraacetate (46) (43 mg) was suspended in 0.5 M NaOH (30 ml) and the whole was stirred vigorously at room temp. for 3 hr. The resulting soln was neutralized with Amberlite IR-120 (H^+ -form) and concd *in vacuo* to give a residue (27 mg), which on prep. TLC

(CHCl₃-MeOH, 7:3, two developments) yielded [7-²H]-7-epiloganic acid (**38**) (18.2 mg) as a white powder. ¹H NMR: δ 1.13 (d, *J* = 6.3 Hz, 10-H₃), 3.61–3.92 (m, 6'-H₂), 4.66 (d, *J* = 7.8 Hz, 1'-H), 5.32 (d, *J* = 5.1 Hz, 1-H), 7.41 (d, *J* = 1.2 Hz, 3-H).

Administration of ²H-labelled 4, 5, 20, 31 and 38 to G. mollugo. Each ²H-labelled compound was dissolved in H₂O (4 ml) and administered hydroponically to 15–20 terrestrial parts (each ca 15–20 cm in length) of the plants in May. After 4 or 6 days, the plants were extracted with MeOH (200 ml × 4) for 20 min under reflux. The MeOH extracts were concd *in vacuo*. The residue was taken up in H₂O (100 ml), and insoluble materials were removed by filtration. The filtrate was transferred to an activated charcoal (6 g) column and eluted successively with H₂O (400 ml) and MeOH (500 ml). Concn of the MeOH eluate gave a glucoside fraction, which was subjected to prep. TLC (four plates, CHCl₃-MeOH 17:3, three developments). The most mobile band gave asperuloside (**2**) as colourless needles. The middle band afforded secogalioside (**36**) as a white powder. The least mobile band furnished a carboxylic acid fraction, which was treated with CH₂N₂. The reaction mixture was concd *in vacuo* and then subjected to prep. TLC (CHCl₃-MeOH, 4:1, two developments) to yield geniposide (**1**) as colourless needles. ²H NMR (2): δ 5.79 (7-²H), 4.65 (10-²H) (both originating from [7,8,10-²H₃]-4); δ 5.79 (7-²H) (originating from [7-²H]-5).

Administration of ²H-labelled 4 and 20 to G. spurium var. echinospermon. Each ²H-labelled compound was dissolved in H₂O (4 ml) and administered hydroponically to 17–18 terrestrial parts (each ca 15–20 cm in length) of *G. spurium* var. *echinospermon* plants in May. After 4 days, the plants were extracted with MeOH (100 ml × 4) under reflux for 20 min. The combined extracts were concd *in vacuo*. The residue was taken up in H₂O (50 ml) and insoluble materials were filtered off. The filtrate was transferred to an activated charcoal (8 g) column and eluted successively with H₂O (400 ml), 5%, 10%, 20%, 30% MeOH-H₂O (each 200 ml). The MeOH eluate gave a glucoside fraction, which on prep. TLC (CHCl₃-MeOH, 17:3, four developments) yielded asperuloside (**2**) as colourless needles. ²H NMR (2): δ 5.79 (7-²H), 4.64 (10-²H) (both originating from [7,8,10-²H₃]-4); δ 4.64 (10-²H) (originating from [10-²H₃]-20).

Administration of ²H-labelled 32 and 33 to D. crenata. Each ²H-labelled compound was dissolved in H₂O (1.5 ml) and administered hydroponically to three young twigs (each 10–12 cm in length with many leaves) of *D. crenata* in Oct. After 24 hr, the twigs were cut into pieces and extracted with MeOH (50 ml × 4) under reflux for 20 min. The combined MeOH extracts were concd *in vacuo*. The residue was taken up in H₂O (50 ml) and insoluble materials were removed by filtration. The filtrate was

transferred to an activated charcoal (3 g) column and eluted with H₂O (200 ml) and MeOH (300 ml). The MeOH eluate gave a glucoside fraction which was acetylated. The product was subjected to prep. TLC (C₆H₆-Et₂O, 5:2, two developments). Of two major bands, the more mobile one afforded deutzioside pentaacetate (**48**) as colourless needles. ²H NMR: δ 1.48 (11-²H) (originating from both [11-²H]-32 and -33).

Acknowledgement—This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, to whom we express our gratitude.

REFERENCES

1. Inouye, H., Ueda, S., Aoki, Y. and Takeda, Y. (1972) *Chem. Pharm. Bull.* **20**, 1287.
2. Inouye, H., Ueda, S. and Takeda, Y. (1972) *Chem. Pharm. Bull.* **20**, 1305.
3. Inouye, H., Ueda, S., Uesato, S. and Kobayashi, K. (1978) *Chem. Pharm. Bull.* **26**, 3384.
4. Inouye, H. (1978) *Planta Medica* **33**, 193.
5. Uesato, S., Matsuda, S. and Inouye, H. (1984) *Chem. Pharm. Bull.* **32**, 1671.
6. Uesato, S., Matsuda, S. and Inouye, H. (1984) *Yakugaku Zasshi* **104**, 1232.
7. Uesato, S., Kanomi (née Matsuda), S., Iida, A., Inouye, H. and Zenk, M. H. (1986) *Phytochemistry* **25**, 839.
8. Uesato, S., Matsuda, S., Iida, A. and Inouye, H. (1984) *Chem. Pharm. Bull.* **32**, 3764.
9. Damtoft, S. (1981) *J. Chem. Soc. Chem. Comm.* 228.
10. Damtoft, S. (1983) *Phytochemistry* **22**, 1929.
11. Uesato, S., Ueda, S., Kobayashi, K., Miyauchi, M. and Inouye, H. (1984) *Tetrahedron Lett.* **25**, 573.
12. Uesato, S., Ueda, S., Kobayashi, K., Miyauchi, M., Itoh, H. and Inouye, H. (1986) *Phytochemistry* **25**, 2309.
13. Bock, K., Jensen, S. R. and Nielsen, B. J. (1976) *Acta Chem. Scand.* **B30**, 743.
14. Uesato, S., Ueda, M., Inouye, H., Kuwajima, H., Yatsuzuka, M. and Takaishi, K. (1984) *Phytochemistry* **23**, 2535.
15. Uesato, S., Kobayashi, K. and Inouye, H. (1982) *Chem. Pharm. Bull.* **30**, 3942.
16. Inouye, H., Yoshida, T., Tobita, S. and Okigawa, M. (1970) *Tetrahedron* **26**, 3905.
17. Battersby, A. R., Hall, E. S. and Southgate, R. (1969) *J. Chem. Soc. C* 721.
18. Damtoft, S., Jensen, S. R. and Nielsen, B. J. (1983) *Biochem. Soc. Trans.* **11**, 593.